8 completed. 8 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 8 | Completed 8 |
Follow Fabry Disease: new trials by email Literature Review of Fabry Disease trials Research Report on Fabry Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Prospective Study to Investigate Safety and Tolerability of Shorter Infusion of Fabrazyme AGALSIDASE BETA (GZ419828), Acetaminophen, Diphenhydramine - Fabry's Disease | Phase 4 | Completed | Sanofi | 8 | 2023-11-10 | 2025-10-21 |
| China Post-marketing Surveillance (PMS) Study of Fabrazyme® Agalsidase beta - Fabry Disease | Phase 4 | Completed | Genzyme, a Sanofi Company | 22 | 2021-10-13 | 2025-09-11 |
| A Study Evaluating Glycosphingolipid Clearance in Patients Treated With Agalsidase Alfa Who Switch to Agalsidase Beta Agalsidase beta - Fabry Disease | Phase 4 | Completed | Genzyme, a Sanofi Company | 15 | 2012-04-01 | 2014-07-10 |
| A Safety and Efficacy Study of Fabrazyme® Replacement Therapy in Patients With Cardiac Fabry Disease Agalsidase beta - Fabry Disease | Phase 4 | Completed | Genzyme, a Sanofi Company | 6 | 2005-07-01 | 2015-05-12 |
| Replagal Enzyme Replacement Therapy for Adults With Fabry Disease Replagal (Agalsidase Alfa), Replagal - Fabry Disease | Phase 4 | Completed | National Institute of Neurological Disorders and Stroke (NINDS) | 25 | 2004-11-01 | 2008-03-04 |
| A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease agalsidase beta - Fabry Disease | Phase 4 | Completed | Genzyme, a Sanofi Company | 67 | 2004-01-01 | 2015-04-02 |
| Ophthalmic Findings During 10-year Enzyme Substitution of Danish Fabry Patients. Enzyme replacement - Fabry Disease | Phase 4 | Completed | Copenhagen University Hospital, Rigshospitalet | 39 | 2001-09-01 | 2014-10-28 |
| A Study of the Safety and Efficacy of Fabrazyme (Agalsidase Beta) as Compared to Placebo in Patients With Advanced Fabry Disease Fabrazyme (agalsidase beta), Placebo - Fabry Disease | Phase 4 | Completed | Genzyme, a Sanofi Company | 82 | 2001-02-01 | 2013-12-27 |
Stroke (1)
Brain Diseases (8) · Brain Diseases, Metabolic (8) · Brain Diseases, Metabolic, Inborn (8) · Cardiovascular Diseases (8) · Central Nervous System Diseases (8) · Cerebral Small Vessel Diseases (8) · Cerebrovascular Disorders (8) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (8) · Genetic Diseases, Inborn (8) · Genetic Diseases, X-Linked (8) · Lipid Metabolism Disorders (8) · Lipid Metabolism, Inborn Errors (8) · Lipidoses (8) · Lysosomal Storage Diseases (8) · Lysosomal Storage Diseases, Nervous System (8)
agalsidase beta (7) · agalsidase alfa (2) · Acetaminophen (1) · Cetirizine (1) · Dexamethasone (1) · Diphenhydramine (1) · Enzyme Replacement Therapy (1) · Loratadine (1) · fexofenadine (1) · montelukast (1)
Genzyme, a Sanofi Company (5) · Copenhagen University Hospital, Rigshospitalet (1) · National Institute of Neurological Disorders and Stroke (NINDS) (1) · Sanofi (1)
United States (5) · Canada (2) · Czechia (2) · Hungary (2) · Poland (2) · United Kingdom (2) · China (1) · Denmark (1) · Japan (1)
Ulla Feldt-Rasmussen, MD, DMSc (1)